Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease

<p>Several Cochrane Reviews evaluate treatments for sickle cell disease, which can cause a huge burden for patients and their families. The review on the effects of hydroxyurea was updated in September 2022 by Angela Rankine-Mullings from the Sickle Cell Unit, Caribbean Institute for Health Research at The University of the West Indies in Jamaica and Sarah Nevitt, from the Department of Health Data Science, University of Liverpool in UK. We asked Angela to outline the need for the review and its latest findings in this podcast.</p>